Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model

International Journal of Cancer

Volumn 80, Issue 5, 1999, Pages 781-790

  Cormier, Janice N ^a   Panelli, Monica C ^a   Hackett, Julia A ^b   Bettinotti, Maria P ^b   Mixon, Arnold ^a   Wunderlich, John ^a   Parker, Linda L ^a   Restifo, Nicholas P ^a   Ferrone, Soldano ^c   Marincola, Francesco M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0032928064     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A     Document Type: Article

References (19)

1. CHEN, Y.-T., STOCKERT, E., TSANG, S., COPLAN, K.E. and OLD, L.J., Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. nat. Acad. Sci. USA, 92, 8125-8129 (1995).
2. CORMIER, J.N., HIJAZI, Y.M., ABATI, A., FETSCH, P., BETTINOTTI, M., STEINBERG, S.M., ROSENBERG, S.A. and MARINCOLA, F.M., Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer, 75, 517-524 (1998).
3. CORMIER, J.N., SALGALLER, M.L., PREVETTE, T., BARRACCHINI, K.C., RIVOLTINI, L., RESTIFO, N.P., ROSENBERG, S.A. and MARINCOLA, F.M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/MelanA. Cancer J. Sci. Am., 3, 37-44 (1997).
4. FERRONE, S. and MARINCOLA, F.M., Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, 16, 487-494 (1995).
5. GARRIDO, F. and 22 OTHERS, HLA and cancer. In: Proceedings of the XII HLA International Workshop, EDK, Sèvres, France (1997).
6. + cytotoxic T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer, 66, 470-476 (1996).
7. KAWAKAMI, Y., ELIYAHU, S., JENNINGS, C., SAKAGUCHI, K., KANG, X., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., APPELLA, E. and ROSENBERG, S.A., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154, 3961-3968 (1995).
8. MARINCOLA, F.M., HIJAZI, Y.M., FETSCH, P., SALGALLER, M.L., RIVOLTINI, L., CORMIER, J., SIMONIS, T.B., DURAY, P.H., HERLYN, M., KAWAKAMI, Y. and ROSENBERG, S.A., Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother., 19, 192-205 (1996a).
9. MARINCOLA, F.M., RIVOLTINI, L., SALGALLER, M.L., PLAYER, M. and ROSENBERG, S.A., Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J. Immunother., 19, 266-277 (1996b).
10. MARINCOLA, F.M., SHAMAMIAN, P., ALEXANDER, R.B., GNARRA, J.R., TURETSKAYA, R.L., NEDOSPASOV, S.A., SIMONIS, T.B., TAUBENBERGER, J.K., YANNELLI, J., MIXON, A. and ROSENBERG, S.A., Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol., 153, 1225-1237 (1994).
11. NISTICÓ, P., MOULESE, M., MAMMI, C., BENEVOLO, M., DELBELLO, D., RUBLU, O., GENTILE, F.P., BOTTI, C., VENTURA, I. and NATALI, P.G., Low frequency of ErbB-2 protooncogene overexpression in human leukocyte antigen A2 positive breast cancer patients. J. nat. Cancer Inst. 89, 319-321 (1997).
12. PARKER, K.C., BEDNAREK, M.A. and COLIGAN, J.E., Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol., 152, 163-175 (1994).
13. PLAYER, M.A., BARRACCHINI, K.C., SIMONIS, T.B., RIVOLTINI, L., ARIENTI, F., CASTELLI, C., MAZZOCCHI, A., BELLI, F. and MARINCOLA, F.M., Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother., 19, 357-363 (1996).
14. RESTIFO, N.P., MARINCOLA, F.M., KAWAKAMI, Y., TAUBENBERGER, J., YANNELLI, J.R. and ROSENBERG, S.A., The loss of functional b2-microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J. nat. Cancer Inst., 88, 100-108 (1996).
15. RIVOLTINI, L., BARACCHINI, K.C. VIGGIANO, V., KAWAKAMI, Y., SMITH, A., MIXON, A., RESTIFO, N.P., TOPALIAN, S.L., SIMONIS, T.B., ROSENBERG, S.A. and MARINCOLA, F.M., Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res., 55, 3149-3157 (1995).
16. ROSENBERG, S.A., Cancer vaccines based on the identification of genesencoding cancer regression antigens. Immunol. Today, 18, 175-182 (1997).
17. SCHEIBENBOGEN, C., WEYERS, I., RUITER, D.J., WILLHAUCK, M., BITTINGER, A. and KEIHOLZ, U., Expression of gp100 in melanoma metastases resected before and after treatment with IFNα and IL-2. J. Immunother., 19, 175-180 (1996).
18. SYKULEV, Y., JOO, M., VTURINA, I., TSOMIDES, T.J. and EISEN, H.N., Evidence that a single peptide - MHC complex on a target cell can elicit a cytolytic T cell response. Immunity, 4, 565-571 (1996).
19. YOSHINO, I., PEOPLES, G.E., GOEDEGEBUURE, P.S., MAZIARZ, R. and EBERLEIN, T.J., Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J. Immunol., 152, 2393-2400 (1994).